Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
Explore this paper's citation graph
Summary
Current first-line treatment options are discussed, biomarker research for personalized therapy is ongoing for each of these treatment modalities, and an outlook on (combination) therapies the authors expect to become relevant in the near future is given.
- Type
- review
- Published
- 2018-06-01
- Cited by
- 85
- References
- 142
- Access
- Open access
- OpenAlex
- https://openalex.org/W2768103628
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13654825
Keywords
Medicine, Melanoma, Disease, Targeted therapy, Oncology
References
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
- Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma
- Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center and University Hospital of Lausanne experience
- Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia.
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Tanning bed exposure increases the risk of malignant melanoma
- Genomic Classification of Cutaneous Melanoma
- Improved overall survival in melanoma with combined dabrafenib and trametinib.
- Prognostic factors for survival in melanoma patients with brain metastases
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma
- Primary mucosal melanoma.
- RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
- Neoantigens in cancer immunotherapy
- Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma
- Resistance to Raf inhibition in cancer
- Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
Cited by
- MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
- EV20‐mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma
- The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
- Hyperthermia induces therapeutic effectiveness and potentiates adjuvant therapy with non-targeted and targeted drugs in an in vitro model of human malignant melanoma
- Long non-coding RNA CASC15 promotes melanoma progression by epigenetically regulating PDCD4
- Retrospective study of patients with cutaneous melanoma treated at the Federal University of São Paulo.
- Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
- Oxidative stress and antioxidants in the pathophysiology of malignant melanoma
- Advanced stage melanoma therapies: Detailing the present and exploring the future.
- Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD‐1/PD‐L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells
- Heme oxygenase 1 facilitates cell proliferation via the B-Raf-ERK signaling pathway in melanoma
- Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma.
- Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study
- Cripto-1: potential target for cancer immunotherapy?!
- Long noncoding RNA ZFAS1 promotes tumorigenesis through regulation of miR-150-5p/RAB9A in melanoma.
- Targeting the ERK Signaling Pathway in Melanoma
- Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
- Clinical significance of prognostic nutritional index (PNI) in malignant melanoma
- MiR-150-5p regulates melanoma proliferation, invasion and metastasis via SIX1-mediated Warburg Effect.
- Hyperthermia Suppresses Post - In Vitro Proliferation and Tumor Growth in Murine Malignant Melanoma and Colon Carcinoma
Related papers
- Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients.
- Inhibition of leukocyte migration in agarose by KC1 extracts of a human melanoma cell line grown in serum‐free medium
- The melanoma epidemic: more apparent than real?
- Commentary: High-metastatic melanoma cells promote the metastatic capability of low-metastatic melanoma cells via exosomal transfer of miR-411-5p
- Epidermotropic metastatic malignant melanoma.
- Analysis of BRAF Mutation in Primary and Metastatic Melanoma
- [The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study].
- Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma
- Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma
- Immunotherapy or targeted therapy as first-line treatment of patients with advanced/metastatic melanoma with the BRAF mutation — a single-center analysis